MedTrace Logo

Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?

NCT02416570 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2016-09-16

No results posted yet for this study

Summary

This study aims to identify if clarithromycin (CLM) has potential as a widely available and inexpensive treatment for cachexia (the loss of muscle mass) in people with non-small cell lung cancer (NSCLC). Half the participants will receive clarithromycin and half will receive a placebo.

Conditions

Interventions

DRUG

Clarithromycin

DRUG

Placebo

Sponsors & Collaborators

  • Roy Castle Lung Cancer Foundation

    collaborator UNKNOWN

  • University of Nottingham

    lead OTHER

Principal Investigators

  • Andrew Wilcock · University of Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-10-31
Completion
2015-10-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02416570 on ClinicalTrials.gov